Continuing Education Activity

Somatostatinoma is a rare neuroendocrine tumor (NET) with an incidence of 1 in 40 million individuals and accounts for less than 5% of pancreatic NETs (pNETs). This activity outlines the evaluation and treatment of somatostatinoma and highlights the role of the interprofessional team in managing patients with this condition.

Objectives:

• Describe the pathophysiology of somatostatinoma.
• Outline the typical presentation and common exam findings of a patient with somatostatinoma.
• Summarize the typical imaging findings associated with somatostatinoma.
• Explain the importance of care coordination among the interprofessional team to decide management based on prognosis.

Introduction

Somatostatinoma is a rare neuroendocrine tumor (NET) with an incidence of 1 in 40 million individuals[1] and accounts for less than 5% of pancreatic NETs (pNETs).[2] The tumor was first described in 1977 in a 46-year-old woman in the head of the pancreas.[3] The tumor originates from the delta cells of the pancreas and predominantly contains somatostatin with trace quantities of other pancreatic hormones such as insulin, glucagon, gastrin, and vasoactive intestinal polypeptide. It remains localized to the pancreas in 56 to 70% of the cases, out of which 36% occur in the head, 14% in the pancreatic body, and 32% in the tail.[4] Other common sites include duodenum (19%), ampulla of Vater (3%), and small bowel (3%).[5] Reports exist of rare instances of extra-gastrointestinal primaries in the lungs, kidneys, and thyroid.[6]

Etiology

Somatostatinoma can be sporadic or may occur in association with neurocutaneous syndromes such as multiple endocrine neoplasia type 1 (the commonest, 40 to 50% of cases), neurofibromatosis type 1 (NF1), and Von Hippel-Lindau syndrome.[4][6] Moreover, a variety of chromosomal aberrations, including loss of heterozygosity at chromosome 11q, 6q, and allelic loss at chromosome 3p, are implicated in the pathogenesis of this disease.[4]

Epidemiology

Somatostatinoma commonly presents in late adulthood between 40 and 60 years of age with no gender predilection.[7][5]

Pathophysiology

Somatostatinoma can be functional or non-functional. Non-functional tumors are common in the duodenum and are identified incidentally or from mechanical obstruction of the biliary tree.[8][9][1] Functional or secretory tumors are common in the pancreas and are diagnosed with the clinical effects of somatostatin.[9] Somatostatin exerts an inhibitory effect on pituitary hormones such as growth hormone and thyroid-stimulating hormone.[5] In the neuro gastrointestinal system, somatostatin suppresses the release of glucagon, pancreatic polypeptide, cholecystokinin, gastrin, secretin, cholecystokinin, vasoactive intestinal polypeptide, gastric inhibitory polypeptide, motilin, glucagon, and neurotensin.[5] It has a direct inhibitory effect on gastric acid secretion, splanchnic perfusion, gastric emptying, gallbladder contractility, bile flow, and bowel motility.[5][10] 

Histopathology

Pancreatic tumors are generally larger and more malignant than their duodenal counterparts.[11] Under light microscopy, most tumors show well-differentiated islet cell or carcinoid tumor morphology, while some show a mixed pattern of differentiated and anaplastic cells.[7] Psammoma bodies are concentric lamellated calcified structures commonly visualized in duodenal tumors more than the pancreatic tumors.[12] Neurosecretory granules are visible in the cytoplasm surrounding the Golgi complex and endoplasmic reticulum under electron microscopy[4], and immunohistochemistry is typically positive for somatostatin and non-specific neuroendocrine markers such as synaptophysin, neuron-specific enolase, chromogranin, and serotonin.[1][7] In one-fourth of the cases, the tumor is positive for other pancreatic hormones such as insulin, calcitonin, gastrin, glucagon, and vasoactive intestinal polypeptide.[6] Immunohistochemistry for Ki-67 (MIB-1) is mandatory to grade the tumor based on WHO classification.[13] WHO has classified gastro-entero-pancreatic tumors into grade 1 – Ki-67 less than or equal to 2%, grade 2 – Ki-67 3% to 20%, grade 3 – Ki-67 over 20%, mixed adenocarcinoma, and neuroendocrine carcinoma.[14]

History and Physical

Non-functional tumors are frequently asymptomatic. Later in the course of the disease, they may present with abdominal pain, vomiting, jaundice, and steatorrhea due to the mechanical effects of the tumor on the biliary and pancreatic drainage.[11] Functional tumors present with the inhibitory effects of somatostatin on the neuroendocrine system. Cholelithiasis is present in almost 70%, and diabetes mellitus in 60% of symptomatic cases.[4] Rarely, they manifest as a triad of diabetes mellitus, cholelithiasis, and steatorrhea, referred to as inhibitory syndrome due to the suppression of insulin, cholecystokinin, and pancreatic exocrine enzymes, respectively.[5][6] The physical examination might reveal icterus in the patients presenting with obstructive jaundice, abdominal tenderness in acute cholecystitis, and neurocutaneous markers such as cafe au lait spots, neurofibromas, and axillary freckling in patients with concomitant NF1.

Evaluation

Early diagnosis of somatostatinoma can be difficult as non-functional tumors often produce no symptoms, and functional tumors present with non-specific symptoms that can masquerade other clinical conditions. Hence most non-functional tumors are discovered incidentally or during the workup of vague gastrointestinal symptoms.[4] Functional tumors typically have elevated fasting serum somatostatin levels (greater than 14 mmol/l).[4] However, it is important to recognize that serum somatostatin levels may also increase in medullary thyroid cancer, lung cancer, pheochromocytoma, and paraganglioma.[15] 24-hour urine level of 5-hydroxy indole acetic acid (5-HIAA), the breakdown product of serotonin, has been used as an alternative in some centers, but the level can be affected by a variety of dietary items and drugs.[16]

Since somatostatinoma usually presents late, tumors are large at diagnosis and are easily visualized using imaging modalities such as CT, MRI, or MRCP.[4] Multiphasic contrast-enhanced CT abdomen is the initial investigation of choice due to the non-invasiveness and the widespread availability.[17] MRI is increasingly in use where pNETs have a low signal density on T1-weighted images and high signal density on T2 weighted images.[18] MRI also has a higher sensitivity than CT to detect small liver metastases.[17] Procedures such as esophagogastroduodenoscopy (EGD), endoscopic retrograde cholangiopancreatography (ERCP), or endoscopic ultrasound (EUS) can be performed to allow luminal visualization and biopsy of the tumor to confirm the diagnosis. EUS offers high sensitivity to detect lesions as small as 0.5 cm and is best indicated for lesions in the head of the pancreas and lesions of the duodenal wall.[4][17]

Treatment / Management

Treatment depends upon the functionality, operability, and staging of the tumor. Surgery with the excision of the primary tumor and all the metastasized lymph nodes is the only curative treatment.[19] Tumors, where nearly 90% are excisable, are treated with curative resection only.[20] Tumors with local and locoregional (liver and lymph node) metastases receive treatment with tumor debulking surgeries and hepatic resection to relieve symptoms secondary to mechanical obstruction and heavy tumor load.[13][20] Depending on the location of the primary tumor, pylorus-preserving proximal pancreaticoduodenectomy, distal pancreatectomy with splenectomy, and Whipple’s procedure are some of the frequently performed procedures.[1][3][21] Grade 3 pNETs are often widely metastasized at diagnosis, thus are generally rendered inoperable.[13] 

Isolated liver metastasis should have treatment with resection or selective hepatic transcatheter arterial embolization (TAE).[17] Prospective trials have shown that long-term survival significantly increases with early and aggressive surgical resection of hepatic metastases.[22] In cases of partially resectable multicentric disease or inoperable liver metastases, ablative procedures such as radiofrequency ablation (RFA), laser-induced thermotherapy,  TAE, transcatheter arterial chemoembolization (TACE), and selective internal radiotherapy (SIRT) are employed in addition to systemic chemotherapy to downstage the tumor.[23]

Differential Diagnosis

Symptoms related to the obstruction of the biliary tree require differentiation from other extrahepatic causes of cholestasis such as choledocholithiasis, choledochal cyst, sclerosing cholangitis, cholangiocarcinoma, pancreatic pseudocysts, and pancreatic adenocarcinoma. Similarly, symptoms secondary to pancreatic insufficiencies such as steatorrhea and insulin-dependent diabetes mellitus should raise suspicion of somatostatinoma in addition to chronic pancreatitis and other pancreatic tumors. 

Medical Oncology

Somatostatin analogs such as octreotide and lanreotide are indicated in functional tumors of any size.[13][24][25] They are also recommended as first-line therapy in nonfunctioning grade 1/2 NETs.[13] Prospective randomized phase III studies have shown that targeted therapy such as tyrosine kinase inhibitor sunitinib malate and mTOR inhibitor everolimus lengthen the time to tumor progression compared to placebo in advanced, low-grade, and intermediate-grade pNET, respectively.[26][27][26]

Chemotherapy is recommended in metastatic grade 2 and any grade 3 tumors. Streptozocin with 5–fluorouracil or doxorubicin is recommended in grade 2 NETs.[13] A multicenter prospective study has shown Streptozocin and doxorubicin to be more effective than Streptozocin and 5-fluorouracil in advanced pNETs.[28] Temozolomide and capecitabine were found to be effective in metastatic, well, or moderately differentiated pancreatic endocrine carcinoma in a retrospective uncontrolled study but the comparative effect with streptozocin combinations remains unknown as yet.[29] Similarly, dacarbazine has demonstrated clinical response in one-third of the patients with advanced pNET in a phase II uncontrolled trial.[30] Platinum-based agents combined with etoposide or irinotecan have proven efficacy in poorly differentiated grade 3 tumors and not well-differentiated tumors in a phase II trial.[13][31]

Staging

Around 75% of the tumors are metastatic at presentation, with liver involvement early in the course of the disease.[4] There are reports of distant metastasis involving the liver.[12] Staging occurs through functional imaging tests such as somatostatin receptor scintigraphy (octreotide scan) and positron emission tomography (PET).[13] Gallium-68 DOTATATE PET has a sensitivity of 94.5% and specificity of 97% for pNETs. They are particularly sensitive to detect bony metastasis compared to octreotide scans (95% vs. 15%, p  < 0.001).[32] As per the American Joint Committee of Cancer (AJCC), pNETs classified into four stages: stage 1 – tumor limited to pancreas, stage 2 – tumor extends beyond pancreas not involving superior mesenteric artery or regional lymph node metastasis, stage 3 – involvement of the celiac axis or superior mesenteric artery, stage 4 – distant metastasis.[33] Endocrine tumors of the foregut classify into the following: stage 1 – size less than or equal to 1 cm with invasion of lamina propria or submucosa; stage 2 – tumors size > 1 cm or invades muscularis propria, pancreas, or retroperitoneum; stage 3 – metastasis of regional lymph node, peritoneum or adjacent structures; stage 4 – distant metastasis.[34]

Prognosis

The 5-year survival rate of patients with pancreatic or periampullary somatostatinoma is 60 to 100% with localized disease and 15 to 60% with metastatic disease.[1] Prognosis depends on the size of the tumor, the degree of cytological differentiation, the amount of residual tumor post-resection, and the extent of metastasis.[35][36] In patients who underwent resection, the 5-year survival rates for stages I, II, III, and IV were 89.9%, 82.6%, 75.8%, and 56.9%, respectively.[37] In a retrospective study on patients with liver metastases, the presence of bone metastasis significantly decreased the median survival (15.4–62.1 vs. 18.2–166.3 months, p < 0.0001).[38]

Complications

Systemic complications include diabetes mellitus, cholelithiasis, iron deficiency anemia, macrocytic anemia, deficiency manifestations of fat-soluble vitamins A, D, E, and K such as night blindness, osteopenia, and bleeding, respectively. Diabetes mellitus is usually mild, and ketoacidosis is rare. It is treated with diet and/or oral hypoglycemic agents or with small doses of insulin.[7] Even if patients do not present with cholelithiasis, prophylactic cholecystectomy is often performed during the initial surgical exploration due to the high prevalence of cholelithiasis among these patients, especially if somatostatin analogs are indicated for treatment.[24] 

Locally, the tumor can lead to obstructive hyperbilirubinemia and gastrointestinal bleeding. 

Postoperative and Rehabilitation Care

Follow-up is recommended for a minimum of 10 years.[19] For fully resected, well-differentiated, or moderately differentiated stage I – III gastroenteropancreatic NETs, consensus recommendation from international multidisciplinary working group exists to guide surveillance using cross-sectional imaging and biomarker testing.[19] Follow-up with cross-sectional imaging (triple-phase CT of the abdomen) or MRI is recommended for pancreatic and midgut NET annually for the first three years, then every 1 to 2 years.[19] More frequent surveillance is recommended for the Ki-67 mitotic index greater than 10% or lymph node positivity.[19] Follow-up is not routinely recommended for pancreatic tumors with stage I or grade 1 tumors and midgut NETS, which are incidental TNM stage 1 or grade 1.[19] Biomarkers are not routinely recommended for surveillance.[19]  European Neuroendocrine Tumor Society (ENETS) recommends functional imaging tests at baseline and every 2 years in grade 1, at 3 months, and yearly for grade 2 to 3 pNETs.[39]

Deterrence and Patient Education

Provider awareness and patient education are necessary for prompt diagnosis of the disease and early initiation of treatment. Reliable online resources such as the American Cancer Society can provide evidence-based information to providers and patients.

Pearls and Other Issues

The rarity of the tumor and the wide variation in the non-specific symptomatology requires a high index of suspicion for initial diagnosis. Early diagnosis is imperative as a significant majority of these tumors are metastatic at presentation. 

Enhancing Healthcare Team Outcomes

Advanced cases of somatostatinoma with hepatic metastases often require an interprofessional approach inclusive of a gastroenterologist, surgeon, and oncologist to evaluate the prognosis and treatment choices between curative procedures and palliative therapy. Pharmacologists review treatment with somatostatin analogs or chemotherapy. Specialty-trained nurses assist with surgery, monitor patients preoperatively, and administer treatment.[40]  [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Williamson JM, Thorn CC, Spalding D, Williamson RC. Pancreatic and peripancreatic somatostatinomas. Ann R Coll Surg Engl. 2011 Jul;93(5):356-60. [PMC free article: PMC3365451] [PubMed: 21943457]

2.

de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012 Feb 07;9(4):199-208. [PMC free article: PMC3544293] [PubMed: 22310917]

3.

Ganda OP, Weir GC, Soeldner JS, Legg MA, Chick WL, Patel YC, Ebeid AM, Gabbay KH, Reichlin S. "Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas. N Engl J Med. 1977 Apr 28;296(17):963-7. [PubMed: 321960]

4.

Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004 Jul;120(1):139-61. [PubMed: 15172200]

5.

Mozell E, Stenzel P, Woltering EA, Rösch J, O'Dorisio TM. Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment. Curr Probl Surg. 1990 Jun;27(6):301-86. [PubMed: 1973365]

6.

Nesi G, Marcucci T, Rubio CA, Brandi ML, Tonelli F. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J Gastroenterol Hepatol. 2008 Apr;23(4):521-6. [PubMed: 17645474]

7.

Vinik AI, Strodel WE, Eckhauser FE, Moattari AR, Lloyd R. Somatostatinomas, PPomas, neurotensinomas. Semin Oncol. 1987 Sep;14(3):263-81. [PubMed: 2820062]

8.

O'Brien TD, Chejfec G, Prinz RA. Clinical features of duodenal somatostatinomas. Surgery. 1993 Dec;114(6):1144-7. [PubMed: 8256221]

9.

Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res. 1999 Mar;18(1):13-22. [PubMed: 10374671]

10.

Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003 Apr;20(3):255-64. [PubMed: 12721505]

11.

Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara Y, Doi T, Watanabe G, Kawaminami K. Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int. 2000 Feb;50(2):146-52. [PubMed: 10792774]

12.

Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol. 1995 May;59(1):67-73. [PubMed: 7745981]

13.

Öberg K, Knigge U, Kwekkeboom D, Perren A., ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30. [PubMed: 22997445]

14.

Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011 Oct;18 Suppl 1:S1-16. [PubMed: 22005112]

15.

Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):737-53. [PMC free article: PMC3627221] [PubMed: 23582916]

16.

Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB., UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012 Jan;61(1):6-32. [PMC free article: PMC3280861] [PubMed: 22052063]

17.

O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008 Mar;34(3):324-32. [PubMed: 17967523]

18.

Tjon A Tham RT, Jansen JB, Falke TH, Lamers CB. Imaging features of somatostatinoma: MR, CT, US, and angiography. J Comput Assist Tomogr. 1994 May-Jun;18(3):427-31. [PubMed: 8188911]

19.

Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E., Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 Nov 01;4(11):1597-1604. [PubMed: 30054622]

20.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC., North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77. [PMC free article: PMC4304762] [PubMed: 23591432]

21.

Zakaria A, Hammad N, Vakhariya C, Raphael M. Somatostatinoma Presented as Double-Duct Sign. Case Rep Gastrointest Med. 2019;2019:9506405. [PMC free article: PMC6532322] [PubMed: 31210994]

22.

Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010 Aug;12(6):427-33. [PMC free article: PMC3028584] [PubMed: 20662794]

23.

Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002 Aug;26(8):985-90. [PubMed: 12016479]

24.

Anene C, Thompson JS, Saigh J, Badakhsh S, Ecklund RE. Somatostatinoma: atypical presentation of a rare pancreatic tumor. Am J Gastroenterol. 1995 May;90(5):819-21. [PubMed: 7733095]

25.

Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):807-17. [PubMed: 16253902]

26.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. [PubMed: 21306237]

27.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K., RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23. [PMC free article: PMC4208619] [PubMed: 21306238]

28.

Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992 Feb 20;326(8):519-23. [PubMed: 1310159]

29.

Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan 15;117(2):268-75. [PMC free article: PMC4665634] [PubMed: 20824724]

30.

Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001 Aug;12(8):1139-43. [PubMed: 11583197]

31.

Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun;51(6):1033-8. [PubMed: 16865563]

32.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2016 Feb 20;34(6):588-96. [PMC free article: PMC4872030] [PubMed: 26712231]

33.

Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J, Yu X. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol. 2017 Jan 20;35(3):274-280. [PubMed: 27646952]

34.

Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B., all other Frascati Consensus Conference participants. European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006 Oct;449(4):395-401. [PMC free article: PMC1888719] [PubMed: 16967267]

35.

Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P, Ruszniewski P. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998 Sep;43(3):422-7. [PMC free article: PMC1727238] [PubMed: 9863490]

36.

House MG, Yeo CJ, Schulick RD. Periampullary pancreatic somatostatinoma. Ann Surg Oncol. 2002 Nov;9(9):869-74. [PubMed: 12417508]

37.

Li X, Gou S, Liu Z, Ye Z, Wang C. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis. Cancer Med. 2018 Mar;7(3):626-634. [PMC free article: PMC5852336] [PubMed: 29380547]

38.

Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. J Nucl Med. 2016 Jan;57(1):34-40. [PubMed: 26471695]

39.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M., Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255-265. [PubMed: 28237989]

40.

Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000 Apr;190(4):432-45. [PubMed: 10757381]

Disclosure: Abbinaya Elangovan declares no relevant financial relationships with ineligible companies.

Disclosure: Priyanka Mathias declares no relevant financial relationships with ineligible companies.

Disclosure: Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.